VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901

NEXT STORY
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer
PREV STORY
Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Merit Medical Signs Agreement to Acquire Cianna Medical, Inc.

SOUTH JORDAN, Utah, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: ...

author_avatar
NASDAQ Market News

Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections

BOSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that ...

author_avatar
NASDAQ Market News

MedAustron selected C-RAD Catalyst PT

MedAustron selected C-RAD Catalyst PT C-RAD announced today that it signed a purchasing agreement ...

author_avatar
NASDAQ Market News